Penwest Pharmaceuticals says that Robert J. Hennessy is stepping down as CEO but remains as a director of the company.
Osteotech announced that Richard W. Bauer, Osteotech's CEO, has decided to accelerate his previously disclosed retirement plans and will retire at the end of December 2005.
Celtic Pharmaceutical has named Dr. Patrick O'Connor, Ph.D., FRCP (Edin.), as managing director and head of clinical development at Celtic Pharma Development Services, the development arm of Celtic Pharmaceutical Holdings.
Renovis announced that Chief Medical Officer Randall W. Moreadith, M.D., Ph.D., will leave the company effective December 16, 2005. Renovis did not announce immediate plans for a replacement.
WEX Pharmaceuticals announced that Michael Chen has given notice to resign from his position as interim CFO on November 30, 2005 for personal reasons. Chen took the position in August on a part time interim basis as the company conducted a search for a permanent CFO.
ALTANA Chemie has appointed Martin Babilas as a member of the management board effective January 1, 2006. He will succeed Gerd Buescher on April 1, 2006, as CFO.
InNexus Biotechnology has named Dr. Heinz Kohler VP of research. Dr. Kohler was instrumental in the start-up phase of IDEC Pharmaceuticals as the director of research.
VIVUS has named Wesley W. Day, Ph.D., VP of clinical development. Day has more than 12 years experience with Pfizer.
Mary Katherine Wold has been promoted to the position of senior VP, tax and treasury, Wyeth. Wyeth has also elected Victor F. Ganzi to its board of directors.
Cardium Therapeutics announced the addition of several positions: Dr. Patricia L. Novak has joined the company as VP, program development, Ted Williams as VP, manufacturing and technical operations, and Anthony Andrasfay as VP, clinical operations.
Takeda Pharmaceuticals North America has named Jeanine Jiganti as chief compliance officer. Jiganti joins Takeda from Illinois, where she was a member of the senior management team as the general counsel and ethics officer for the Department of Commerce and Economic Opportunity.
AEterna Zentaris has appointed Jurgen Ernst, former worldwide general manager, pharmaceutical sector of Solvay, as vice chairman of the board.
Advanced Cell Technology has appointed Dr. Erkki Ruoslahti, former president of The Burnham Institute, and Dr. Alan G. Walton, a senior general partner of Oxford Bioscience Partners, as independent directors of the company.
NovaDel Pharma announced that board of directors' member and non-executive chairman of the board Robert G. Savage will not to stand for re-election at the company's 2006 annual meeting of shareholders.
Phytomedics has named Dr. Mark W. Pierce, M.D., Ph.D., to its board of directors.
PRA International has elected Judith Hemberger to its board of directors.
Anthera Pharmaceuticals announced that David E. Thompson has been appointed to the company's board of directors.
Allos Therapeutics has elected Timothy P. Lynch to its board of directors.
BioMS Medical has elected Bryan McKnight to its board and chair of the audit committee and Gordon Politeski as an adviser to the board pending his nomination as a director at the company's next annual meeting.
Cancer researcher Dr. Robert C. Bast, Jr., has been named to the Scientific Advisory Board of Tanox.